• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Basic and clinical studies on ceftazidime in the pediatric field].

作者信息

Sato Y, Iwata S, Iwasaki Y, Akita H, Murai T, Hayano S, Wakabayashi R, Sunakawa K, Oikawa T, Osano M

出版信息

Jpn J Antibiot. 1984 Mar;37(3):389-406.

PMID:6376852
Abstract

Basic and clinical studies were made on ceftazidime (CAZ) in pediatric field, and the following results were obtained. The antibacterial activity of CAZ against clinically isolated and maintained strains was examined. CAZ was unequivocally more active than CEZ and CMZ against Gram-negative rods, with MIC distribution similar to that of CTX, except for that for P. aeruginosa. The MIC of CAZ was lower than that of CTX for P. aeruginosa. Compared with the MICs of CEZ, CMZ and CTX, CAZ showed slightly higher MICs for Gram-positive bacteria. The blood concentrations of CAZ, at 0.25, 0.5, 1, 2, 4 and 6 hours after a one shot intravenous injection of 10 mg/kg of CAZ were 64.9, 36.9, 28.3, 14.7, 4.92 and 2.42 micrograms/ml, respectively, with the half-life of 1.27 hours. The blood concentrations of CAZ, at 0.25, 0.5, 1, 2, 4 and 6 hours after a 1-hour drip infusion of 10 mg/kg of CAZ were 16.6, 24.5, 41.4, 17.1, 5.38 and 2.62 micrograms/ml, respectively, with the half-life of 1.28 hours. The blood concentrations of CAZ, at 0.25, 0.5, 1, 2, 4 and 6 hours after a one shot intravenous injection of 20 mg/kg of CAZ were 73.1, 60.8, 39.3, 17.3, 8.23 and 4.45 micrograms/ml, respectively, with the half-life of 1.42 hours. The blood concentrations of CAZ, at 0.5, 1, 2, 4 and 6 hours after a 1-hour drip infusion of 20 mg/kg of CAZ were 55.1, 69.0, 32.1, 11.4 and 4.56 micrograms/ml, respectively, with the half-life of 1.27 hours. Urinary recovery rate of CAZ during the first 6 hours after a one shot intravenous injection of 10 mg/kg of CAZ was 86.7%. CAZ was administered to 17 children with infections, and the clinical response was excellent or good in 94%. CAZ was bacteriologically effective in 14 patients, all bacteria having been eradicated in them. The bacteria were E. coli in 10 patients, H. influenzae in 2, P. aeruginosa in 1 and S. pneumoniae in 1. As for side effects, slight elevation in GOT was observed in 1 case and eosinophilia, in another case.

摘要

相似文献

1
[Basic and clinical studies on ceftazidime in the pediatric field].
Jpn J Antibiot. 1984 Mar;37(3):389-406.
2
[Fundamental and clinical studies on ceftazidime in the field of pediatrics].头孢他啶在儿科领域的基础与临床研究
Jpn J Antibiot. 1984 Mar;37(3):490-511.
3
[Laboratory and clinical studies on ceftazidime in the field of pediatrics].头孢他啶在儿科领域的实验室及临床研究
Jpn J Antibiot. 1984 Mar;37(3):469-84.
4
[Fundamental and clinical studies on ceftazidime in the field of pediatrics].
Jpn J Antibiot. 1984 Mar;37(3):423-59.
5
[Laboratory and clinical studies of ceftazidime in the pediatric field].
Jpn J Antibiot. 1984 Mar;37(3):512-23.
6
[Fundamental and clinical evaluation of ceftriaxone in the pediatric field].
Jpn J Antibiot. 1984 Nov;37(11):2111-30.
7
[Fundamental and clinical studies on ceftazidime in the field of paediatrics].头孢他啶在儿科领域的基础与临床研究
Jpn J Antibiot. 1984 Mar;37(3):485-9.
8
[Bacteriological, pharmacokinetic and clinical evaluations of cefpirome sulfate in the pediatric field. Pediatric Study Group of Cefpirome].
Jpn J Antibiot. 1991 Jan;44(1):84-109.
9
[Clinical evaluation of ceftazidime in paediatrics].
Jpn J Antibiot. 1984 Mar;37(3):524-36.
10
[Fundamental and clinical studies on cefuzoname in the pediatric field].
Jpn J Antibiot. 1987 Apr;40(4):843-65.

引用本文的文献

1
Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.头孢他啶。对其抗菌活性、药代动力学特性及治疗用途的综述。
Drugs. 1985 Feb;29(2):105-61. doi: 10.2165/00003495-198529020-00002.